欧美日韩亚洲一区二区三区四区 ,91尤物视频盛宴,国产综合色产在线观看,国产欧美久久久精品影院,国内精品伊人久久久影视,欧美成人精品免费播放,国产麻豆精品一区二区三区v视界

Shanghai, China——Minos? Abdominal Aortic Stent-Graft and Delivery System ( “Minos?”) independently developed by Shanghai MicroPort Endovascular MedTech Co., Ltd (“Endovasctec?”) successfully gained CE certificate on September 12, 2019. It is the third CE certificate product following the Hercules? Balloon Inflation Catheter and Reewarm? PTA Balloon Dilatation Catheter, and the first CE certificate for the aortic stent graft products.

As a new generation of abdominal aortic stent graft, independently developed by Endovasctec?, Minos? is applicable to abdominal aortic aneurysm with proximal aneurysm neck longer than 15mm. It is the only domestic product with the independent intellectual property right and reduces the outer diameter of the sheath to 14F (<5mm), which significantly reduces the vascular access requirement of Endovascular Aneurysm Repair ( “EVAR”). Minos? with the core technology such as the laser-cutting bare stent with barbs, seamless graft weaved by multifilament yard, mainbody multiple mini-stent, helical limb stent, can meet the requirement of the abdominal aortic aneurysm with complex anatomy. It reduces the incidence of common complications such as stent migration, endoleak, and limb stent occlusion, further reducing the risk of long-term secondary intervention. Minos? has a three-piece design and can be flexibly assembled to meet different size requirement. 

Minos? was approved by National Medical Products Administration (NMPA) on March 19, 2019. Minos? provides a better solution for domestic patients with the complex abdominal aortic anatomy, especially for the patients with more access to the arterial stenosis. Zhenghua Miao, president of Endovasctec?, said that “The approval of the Minos? in EU means that Endovasctec? offers doctors more choices in EVAR treatment. Endovasctec? will continue to devote itself to promoting more high quality, innovative high-end medical devices to overseas market and provide patients with more all-round therapeutic schedule.